EVOGENE LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 255.1 ILa | -1.58% |
|
+8.65% | -14.91% |
| Apr. 02 | Evogene Ltd. and The Kitchen FoodTech Hub Establishes Finally Foods Ltd | CI |
| Mar. 20 | Evogene Receives Minimum Bid Price Non-Compliance Notice From Nasdaq | MT |
| Sales 2024 * | 17M 6.37B | Sales 2025 * | 31.5M 11.81B | Capitalization | 33.94M 12.72B |
|---|---|---|---|---|---|
| Net income 2024 * | -20M -7.5B | Net income 2025 * | -17M -6.37B | EV / Sales 2024 * | 2 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.08 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 142 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Evogene Ltd.
More press releases
| 1 day | -1.58% | ||
| 1 week | +8.65% | ||
| Current month | -9.41% | ||
| 1 month | -6.97% | ||
| 3 months | -8.24% | ||
| 6 months | +29.23% | ||
| Current year | -14.91% |
1 week
246.00
261.60
1 month
231.20290.00
Current year
231.20370.00
1 year
189.30610.40
3 years
189.301 466.00
5 years
189.303 350.00
10 years
189.306 067.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01-12-31 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 22-03-31 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 04-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 21-11-16 |
Sarit Firon
CHM | Chairman | 58 | 16-08-10 |
Leon Recanati
BRD | Director/Board Member | 76 | 05-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 255.1 | -1.58% | 9,122 |
| 24-04-24 | 259.2 | +10.39% | 86,598 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 25, 2024 at 07:24 am EDT
More quotes
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Calendar
2024-05-27
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.91% | 33.86M | |
| +1.77% | 42.75B | |
| +47.70% | 41.61B | |
| +12.24% | 41.34B | |
| -8.83% | 26.59B | |
| +7.44% | 25.49B | |
| -23.01% | 18.12B | |
| +30.56% | 12.24B | |
| -1.82% | 11.76B | |
| +8.35% | 11B |
- Stock Market
- Equities
- EVGN Stock
